Nebenwirkungen · Docetaxel Kabi
DOCETAXEL KABI 180 mg/9 ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 206
HOS-215047 · Präparat HOS-155350
MedDRA system Very common adverse Common adverse Uncommon adverse organ classes reactions reactions reactions Infections and Infection (G3/4: 2.4%); infestations Neutropenic infection (G3/4: 2.6%) Blood and Anaemia (G3/4: 3%); lymphatic system Neutropenia disorders (G3/4: 59.2%); Thrombocytopenia (G3/4: 1.6%); Febrile neutropenia (G3/4: NA) Immune system Hypersensitivity disorders (G3/4: 0.6 %) Metabolism and Anorexia (G3/4: 1.5%) nutrition disorders Nervous system Dysgeusia (G3/4: 0.6%); Peripheral motor Syncope (G3/4: 0%); disorders Peripheral sensory neuropathy Neurotoxicity neuropathy (G3/4: 0%) (G3/4: 0%); (G3/4: < 0.1%) Somnolence (G3/4: 0%) Eye disorders Conjunctivitis Lacrimation (G3/4: < 0.1%) increased (G3/4: < 0.1%) Cardiac disorders Arrhythmia (G3/4: 0.2%) Vascular disorders Hot flush (G3/4: 0.5%) Hypotension Lymphoedema (G3/4: 0%); (G3/4: 0%) Phlebitis (G3/4: 0%) Respiratory, Cough (G3/4: 0%) thoracic and mediastinal disorders
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-08-04T15:44:00Z · SHA-256 4ec115d98d201d84de2340a9fdabdd8a6db17b0a20954d72cafab8a7e3eaf6e6 · Passage d04a95eebb5d942f2d1f83088fbbed3e2141d7b37be90b4c72311c78da4b2fa1 · Zeichen 28606–30399 im Abschnitt